<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258153</url>
  </required_header>
  <id_info>
    <org_study_id>NIC-03</org_study_id>
    <nct_id>NCT01258153</nct_id>
  </id_info>
  <brief_title>Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic</brief_title>
  <acronym>no-cry</acronym>
  <official_title>Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Administration of Nepadutant in Infant Colic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IIa study is designed as a multi-centre, multinational, randomised, double-blind,
      placebo controlled study in three parallel groups, with the aim to evaluate the efficacy and
      safety of Nepadutant given at two oral doses once daily for seven days in comparison to
      placebo in the treatment of infantile colic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infant colic is a functional gastrointestinal disorders which affects up to the 30% of the
      infant population; it is primarily characterised by excessive inconsolable crying starting
      without any apparent cause and lasting for several hours per day.

      Current non pharmacological interventions (e.g. message, restriction in maternal diet in
      breast-feeding infants) and pharmacological treatments (simethicone, antimuscarinic drugs)
      are largely unsatisfactory.

      In animal models, Nepadutant reverse the exaggerated intestinal motility and sensitivity,
      induced by different stimuli, without producing inhibitory effects on these functions at
      baseline, suggesting that Nepadutant could have a therapeutic effect with no interference on
      physiological gastrointestinal transit.

      This phase IIa study is designed to evaluate the efficacy of Nepadutant paediatric oral
      solution given once daily at two doses in comparison to placebo.

      The experimental clinical phase encompasses the following periods:

        -  Screening period (no study medication) to be done 7 to 4 days prior to randomisation

        -  Treatment period, lasting seven days with once daily administration

        -  Post treatment period, lasting seven days A safety follow-up visit will be performed
           approximately 1 month after the first administered dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change of the Mean Daily Crying and Fussing Time for Three Consecutive Days While on Treatment Versus Baseline.</measure>
    <time_frame>Baseline and one week</time_frame>
    <description>Efficacy assessment to be measured through &quot;baby's day&quot; diary recorded for three consecutive days while on treatment (i.e. starting from 6 pm on Day 4 and continued for 72 hours) vs baseline (i.e. starting from 6 pm on Day -4 until 1st treatment administration).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of 'Responder' Babies at the End of Treatment Period.</measure>
    <time_frame>baseline and one week</time_frame>
    <description>Response is defined as a decrease of at least 50% of crying and fussing time during the last 3 days on treatment vs baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in the Overall Parental Judgment After the First Dose of Treatment Versus Baseline</measure>
    <time_frame>1 day</time_frame>
    <description>On a daily basis parents expressed an overall judgement on the study treatment effect based on a 6 rate categorical scale from 0 to 5 (where 0 is for &quot;Not at all&quot; and 5 is &quot;Extremely&quot;.
The question was &quot;How frustrating to you was your baby's crying today?&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in the Overall Parental Judgment at the End of Treatment Versus Baseline</measure>
    <time_frame>1 week</time_frame>
    <description>On a daily basis parents expressed an overall judgement on the study treatment effect based on a 6 rate categorical scale from 0 to 5 (where 0 is for &quot;Not at all&quot; and 5 is &quot;Extremely&quot;.
The question was &quot;How frustrating to you was your baby's crying today?&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in the Overall Parental Judgment After Treatment Discontinuation Versus Baseline</measure>
    <time_frame>10 days</time_frame>
    <description>On a daily basis parents expressed an overall judgement on the study treatment effect based on a 6 rate categorical scale from 0 to 5 (where 0 is for &quot;Not at all&quot; and 5 is &quot;Extremely&quot;.
The question was &quot;How frustrating to you was your baby's crying today?&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability Will be Assessed in Terms of Frequency and Severity of AEs as Well as Frequency of Clinically Significant Changes in Physical Examination and Lab Test.</measure>
    <time_frame>up to four weeks</time_frame>
    <description>Safety and tolerability will be assessed for the Safety Population (all patients who received the study drug) in terms of frequency and severity of AEs as well as frequency of clinically significant changes in physical examination and lab test.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Infantile Colic</condition>
  <arm_group>
    <arm_group_label>Nepadutant Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nepadutant High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepadutant oral solution</intervention_name>
    <description>Oral administration once daily for 7 days</description>
    <arm_group_label>Nepadutant Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepadutant oral solution</intervention_name>
    <description>Oral administration once daily for 7 days</description>
    <arm_group_label>Nepadutant High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching Nepadutant oral solution</intervention_name>
    <description>Oral administration once daily for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants with diagnosis of infant colic according to the following modified
             Wessel criterion &quot;paroxysm of irritability, fussing or crying that start and stop
             without obvious cause for &gt;3h/day, &gt;3 days/week for one week&quot;

          -  Age &gt; 4 weeks and &lt; 20 weeks

          -  Infants breast-fed mixed fed or formula fed with a stable dietary regimen

          -  Normal growth

          -  History of no adequate response to conventional treatment alternatives which make the
             infants in need of medical treatment

          -  Willingness to refrain from use of antimuscarinic drugs, simethicone, dimethicone or
             antiacids during the study period.

        Exclusion Criteria:

          -  Clinical evidence of allergies or other diseases which may cause crying and/or
             fussiness or may interfere with absorption or clearance of the drug.

          -  Suspect of gastroesophageal reflux disease (GERD)

          -  Suspect of cow milk allergy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sibylle Koletzko, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dr. v. Haunersches Kinderspital Ludwig Maximilians University D- 80337 München, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. von Haunersches Kinderspital Ludwig Maximilians Universität München</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Patologii Noworodkow, Niemowlat I Kardiologii, Dzieciecy Szpital Kliniczny</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Scientific Clinical Center of Children Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Healthcare Institution Municipal Pediatric health center № 10</name>
      <address>
        <city>Moscow</city>
        <zip>119331</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Scientific Clinical Center of Children Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>123317</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Pediatric Medical Academy</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Institution of Healthcare Municipal Pediatric health center № 35</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199191</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics Department of Clinical sciences Umeå university</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2010</study_first_submitted>
  <study_first_submitted_qc>December 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2010</study_first_posted>
  <results_first_submitted>May 4, 2015</results_first_submitted>
  <results_first_submitted_qc>May 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2015</results_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infantile Colic</keyword>
  <keyword>tachykinin antagonist</keyword>
  <keyword>Nepadutant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>MEN 11420</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nepadutant Low Dose</title>
          <description>Nepadutant oral solution 0.1mg/kg: Oral administration once daily for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Nepadutant High Dose</title>
          <description>Nepadutant oral solution 0.5mg/kg: Oral administration once daily for 7 days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo matching Nepadutant oral solution: Oral administration once daily for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>113 : ITT - defined as the safety population randomised with at least 24h diary recording post 1st dose of study treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Nepadutant Low Dose</title>
          <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Nepadutant High Dose</title>
          <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo matching Nepadutant oral solution: Oral administration once daily for 7 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.03" spread="4.909"/>
                    <measurement group_id="B2" value="11.34" spread="5.147"/>
                    <measurement group_id="B3" value="10.92" spread="4.686"/>
                    <measurement group_id="B4" value="11.1" spread="4.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.22" spread="1.129"/>
                    <measurement group_id="B2" value="5.24" spread="1.267"/>
                    <measurement group_id="B3" value="5.61" spread="1.419"/>
                    <measurement group_id="B4" value="5.35" spread="1.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Feeding Mode</title>
          <description>Feeding mode: 1 data missing in high dose - 0.5mg/kg (37 subjects instead of 38)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Breast Fed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Formula Fed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Fed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change of the Mean Daily Crying and Fussing Time for Three Consecutive Days While on Treatment Versus Baseline.</title>
        <description>Efficacy assessment to be measured through “baby’s day” diary recorded for three consecutive days while on treatment (i.e. starting from 6 pm on Day 4 and continued for 72 hours) vs baseline (i.e. starting from 6 pm on Day -4 until 1st treatment administration).</description>
        <time_frame>Baseline and one week</time_frame>
        <population>112 instead of 113, because 1 subject had no records at baseline and therefore the outcome could not be measured</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant Low Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant High Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change of the Mean Daily Crying and Fussing Time for Three Consecutive Days While on Treatment Versus Baseline.</title>
          <description>Efficacy assessment to be measured through “baby’s day” diary recorded for three consecutive days while on treatment (i.e. starting from 6 pm on Day 4 and continued for 72 hours) vs baseline (i.e. starting from 6 pm on Day -4 until 1st treatment administration).</description>
          <population>112 instead of 113, because 1 subject had no records at baseline and therefore the outcome could not be measured</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.57" spread="89.298"/>
                    <measurement group_id="O2" value="273.6" spread="86.356"/>
                    <measurement group_id="O3" value="283.91" spread="80.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.8" spread="100.97"/>
                    <measurement group_id="O2" value="154.4" spread="102"/>
                    <measurement group_id="O3" value="192.7" spread="85.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-96.9" spread="74.12"/>
                    <measurement group_id="O2" value="-119.2" spread="97.13"/>
                    <measurement group_id="O3" value="-91.2" spread="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of 'Responder' Babies at the End of Treatment Period.</title>
        <description>Response is defined as a decrease of at least 50% of crying and fussing time during the last 3 days on treatment vs baseline.</description>
        <time_frame>baseline and one week</time_frame>
        <population>112 instead of 113, because 1 subject had no records at baseline and therefore the outcome could not be measured</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant Low Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant High Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of 'Responder' Babies at the End of Treatment Period.</title>
          <description>Response is defined as a decrease of at least 50% of crying and fussing time during the last 3 days on treatment vs baseline.</description>
          <population>112 instead of 113, because 1 subject had no records at baseline and therefore the outcome could not be measured</population>
          <units>Responders Rate (% of responders babies)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="55.3"/>
                    <measurement group_id="O3" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in the Overall Parental Judgment After the First Dose of Treatment Versus Baseline</title>
        <description>On a daily basis parents expressed an overall judgement on the study treatment effect based on a 6 rate categorical scale from 0 to 5 (where 0 is for &quot;Not at all&quot; and 5 is &quot;Extremely&quot;.
The question was &quot;How frustrating to you was your baby's crying today?&quot;)</description>
        <time_frame>1 day</time_frame>
        <population>ITT - defined as the safety population randomised with at least 24h diary recording post 1st dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant Low Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant High Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in the Overall Parental Judgment After the First Dose of Treatment Versus Baseline</title>
          <description>On a daily basis parents expressed an overall judgement on the study treatment effect based on a 6 rate categorical scale from 0 to 5 (where 0 is for &quot;Not at all&quot; and 5 is &quot;Extremely&quot;.
The question was &quot;How frustrating to you was your baby's crying today?&quot;)</description>
          <population>ITT - defined as the safety population randomised with at least 24h diary recording post 1st dose of study treatment</population>
          <units>Score range 0-5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Questionnaires completed by parents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.771"/>
                    <measurement group_id="O2" value="-0.68" spread="0.884"/>
                    <measurement group_id="O3" value="-0.34" spread="0.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in the Overall Parental Judgment at the End of Treatment Versus Baseline</title>
        <description>On a daily basis parents expressed an overall judgement on the study treatment effect based on a 6 rate categorical scale from 0 to 5 (where 0 is for &quot;Not at all&quot; and 5 is &quot;Extremely&quot;.
The question was &quot;How frustrating to you was your baby's crying today?&quot;)</description>
        <time_frame>1 week</time_frame>
        <population>ITT - defined as the safety population randomised with at least 24h diary recording post 1st dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant Low Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant High Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in the Overall Parental Judgment at the End of Treatment Versus Baseline</title>
          <description>On a daily basis parents expressed an overall judgement on the study treatment effect based on a 6 rate categorical scale from 0 to 5 (where 0 is for &quot;Not at all&quot; and 5 is &quot;Extremely&quot;.
The question was &quot;How frustrating to you was your baby's crying today?&quot;)</description>
          <population>ITT - defined as the safety population randomised with at least 24h diary recording post 1st dose of study treatment</population>
          <units>Score range 0-5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Questionnaires completed by parents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.909"/>
                    <measurement group_id="O2" value="-1.75" spread="1.186"/>
                    <measurement group_id="O3" value="-1.23" spread="1.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in the Overall Parental Judgment After Treatment Discontinuation Versus Baseline</title>
        <description>On a daily basis parents expressed an overall judgement on the study treatment effect based on a 6 rate categorical scale from 0 to 5 (where 0 is for &quot;Not at all&quot; and 5 is &quot;Extremely&quot;.
The question was &quot;How frustrating to you was your baby's crying today?&quot;)</description>
        <time_frame>10 days</time_frame>
        <population>ITT - defined as the safety population randomised with at least 24h diary recording post 1st dose of study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant Low Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant High Dose</title>
            <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in the Overall Parental Judgment After Treatment Discontinuation Versus Baseline</title>
          <description>On a daily basis parents expressed an overall judgement on the study treatment effect based on a 6 rate categorical scale from 0 to 5 (where 0 is for &quot;Not at all&quot; and 5 is &quot;Extremely&quot;.
The question was &quot;How frustrating to you was your baby's crying today?&quot;)</description>
          <population>ITT - defined as the safety population randomised with at least 24h diary recording post 1st dose of study treatment</population>
          <units>Score range 0-5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Questionnaires completed by parents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="0.857"/>
                    <measurement group_id="O2" value="-1.78" spread="1.176"/>
                    <measurement group_id="O3" value="-1.39" spread="0.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability Will be Assessed in Terms of Frequency and Severity of AEs as Well as Frequency of Clinically Significant Changes in Physical Examination and Lab Test.</title>
        <description>Safety and tolerability will be assessed for the Safety Population (all patients who received the study drug) in terms of frequency and severity of AEs as well as frequency of clinically significant changes in physical examination and lab test.</description>
        <time_frame>up to four weeks</time_frame>
        <population>All patients receiving the study drug (114)</population>
        <group_list>
          <group group_id="O1">
            <title>Nepadutant Low Dose</title>
            <description>Nepadutant oral solution 0.1mg/kg: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Nepadutant High Dose</title>
            <description>Nepadutant oral solution 0.5mg/kg: Oral administration once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matching Nepadutant oral solution: Oral administration once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability Will be Assessed in Terms of Frequency and Severity of AEs as Well as Frequency of Clinically Significant Changes in Physical Examination and Lab Test.</title>
          <description>Safety and tolerability will be assessed for the Safety Population (all patients who received the study drug) in terms of frequency and severity of AEs as well as frequency of clinically significant changes in physical examination and lab test.</description>
          <population>All patients receiving the study drug (114)</population>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nepadutant Low Dose</title>
          <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Nepadutant High Dose</title>
          <description>Nepadutant oral solution: Oral administration once daily for 7 days</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo matching Nepadutant oral solution: Oral administration once daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Hospitalization for Bronchitis in a 10 weeks-old male infant. The investigator considered the SAE as unlikely related to the study drug. It resolved without sequel.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Salivary ipersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gamma -GT abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study cannot be submitted for presentation, abstract, poster exhibition, or publication by the investigator until Menarini Ricerche S.p.A. has reviewed/commented and agreed to any publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Angela Capriati</name_or_title>
      <organization>Menarini Ricerche</organization>
      <phone>+39 05556809990</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

